TRex Bio (NASDAQ:TRXB) Coverage Initiated by Analysts at Wedbush

Analysts at Wedbush began coverage on shares of TRex Bio (NASDAQ:TRXB) in a report issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush‘s price target points to a potential upside of 118.34% from the stock’s previous close.

TRex Bio Price Performance

Shares of NASDAQ:TRXB opened at $13.74 on Monday. TRex Bio has a 12-month low of $13.10 and a 12-month high of $16.56.

Insider Transactions at TRex Bio

In related news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the firm’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the purchase, the insider directly owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.